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Abstract
Background: The HPV prevalence and genotype distribution are important for the estimation of the impact of HPV-based
cervical cancer screening and HPV vaccination on the incidence of diseases etiologically linked to HPVs. The HPV genotype
distribution varies across different geographical regions. Therefore, we investigated the type-specific HPV prevalence in
Czech women and men with anogenital diseases.
Methods: We analyzed 157 squamous cell carcinoma samples, 695 precancerous lesion samples and 64 cervical, vulvar and
anal condylomata acuminate samples. HPV detection and typing were performed by PCR with GP5+/6+ primers, reverse line
blot assay and sequencing.
Results: Thirty different HPV genotypes were detected in our study, HPV 16 being the most prevalent type both in
precancerous lesions (45%) and squamous cell carcinomas (59%). In benign lesions, HPV 6 (72%) was the most common
type. Altogether, 61% of carcinoma samples and 43% of precancerous lesion samples contained HPV 16 and/or 18. The
presence of HPV types related to the vaccinal ones (HPV 31, 45, 33, 52, 58) were detected in 16% of carcinoma samples
and 18% of precancerous lesion samples. HPV 16 and/or 18 were present in 76% of cervical cancer samples, 33% of CIN1,
43% CIN2 and 71% of CIN3 samples. HPV types 6 and/or 11 were detected in 84% samples of condylomata acuminate
samples.
Conclusions: The prevalence of vaccinal and related HPV types in patients with HPV-associated diseases in the Czech
Republic is very high. We may assume that the implementation of routine vaccination against HPV would greatly reduce the
burden of HPV-associated diseases in the Czech Republic.
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Introduction
Human papillomaviruses (HPVs) have been established as
etiological agents of invasive cervical cancer (CC) [1,2] and they
are the most common viral sexually transmitted infection
worldwide. Persistent infection with high-risk (HR) HPVs is
necessary for the development of premalignant lesions and/or
progression of the disease [3]. Furthermore, HPV has carcinogenic
effects at several other anatomical sites in women and men [4].
HPV genotype distribution varies across different populations and
geographical regions [5]. Recently, meta-analyses and systematic
reviews of HPV type distribution in diseases linked to HPV
infections worldwide have been published [6–13]. CC is the
second most common cancer among women worldwide, with
492,800 incident cases during 2002 [14]. The burden of
noncervical anogenital, i.e. anal, vaginal and vulvar, cancers
approximates 53,872 cases worldwide annually (i.e. 28,272 anal
and 25,600 vaginal and vulvar cancer cases). In the Czech
Republic , 990 CC cases, 189 vulvar cancer cases and 121 anal
cancer cases occur annually [15].
In spite of the high burden of cervical cancer in Central and
Eastern Europe [16], few data are available regarding the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21913prevalence of HPV [17–20]. Therefore, our study which collects
the available data on Czech patients with a wide variety of HPV-
associated diseases will contribute to a better understanding of the
HPV type distribution in the Czech Republic. Importantly, it will
help in estimating the potential local impact of HPV vaccines on
the prevention of HPV-associated diseases in women and men.
Materials and Methods
Population studied
Squamous cell cervical carcinoma (SCC) samples as well as
precancerous lesion samples from different anatomical locations
were selected from the biobank of the National Reference
Laboratory for Papillomaviruses in Prague. These samples were
collected between 1993 and 2005, stored at 220uC and analyzed
in previous studies.
Cervical scrape and biopsy specimens were obtained from
women visiting hospital gynecology departments and selected
centers of gynecologic-oncology prevention in the Czech Republic
[21].Thesesettingsarelocated indifferentdistrictsacrossthe Czech
Republic and serve wide catchment areas. Therefore, the patients
included in our study are representative of the population of the
whole of the Czech Republic. Additionally, samples from patients
treated for cervical intraepithelial neoplasia garde 1 to 3 (CIN1/2/
3) were used. The patients characteristics and sample processing
were published before [22]. The classification of all CIN2/3 and
SCC specimens and of the majority of CIN1 (86%) specimens was
done by histology as specified before. Overall, 86 SCC specimens
(patient mean age 49.7 years; age range 28–87 years), 338 CIN1
specimens (mean age 33.8 years; age range 16–76 years), 111 CIN2
specimens (mean age 34.5 years; age range 20–59 years), and 200
CIN3 specimens (mean age 33.9 years; age range 20–66 years) were
selected for the purpose of the present study.
Samples from patients surgically treated in the Department of
Obstetrics and Gynecology of the 2
nd Faculty of Medicine, Charles
University, Prague for squamous cell vulvar carcinoma (VC),
vulvar intraepithelial neoplasia (VIN) and vulvar condylomata
acuminata (VCA) were also included in the study. The patients
characteristics and histological data were published before [23].
For HPV typing, 49 VC samples (patient mean age 70.7 years; age
range 32–95 years), 46 samples from patients with different grades
of usual VIN (u-VIN) (patient mean age 52.5 years; age range 29–
85 years) and 54 VCA samples (patient mean age 30.6; age range
15–59 years) were available.
Twenty-two samples from patients with squamous cell carcino-
ma of the anus (AC) (mean age 64.2 years; age range 47–86 years,
18 women & 4 men) and 10 samples of anal condylomata
acuminata (ACA) samples (patient mean age 41.4 years; age range
21–69 years, 1 woman & 9 men), were analyzed. Details on the
population, sample preparation and pathological classification
were published before [24].
Overall, 157 cancer samples from multiple locations, 695 pre-
malignant neoplasia samples, and 64 condylomata acuminata
samples were included in this study.
Ethic statement
No informed consent was needed from the patient by the course
of law in the Czech Republicbefore 2000. All patients enrolled
after the year 2000 signed an informed consent form and the study
was approved by the institutional ethics committee [25].
HPV detection and genotyping
PCR and reverse line blot hybridization (RLB) were used for the
detection and genotyping of the HPV DNA in samples [26]. RLB
is able to identify 37 different HPV types in a single assay. The
HPV detection was performed in a PCR thermocycler PTC 200
(MJ Research, Inc, Waltham, MA, USA) by the PCR assay with
primers GP5+ and 59-end biotin labelled GP6+ primer which
amplify the 150 bp fragment of the L1 gene. The PCR was
performed for 40 cycles and the biotinylated PCR product was
hybridized with the oligonucleotide probes labelled with the 59-
terminal amino-group. These probes were covalently linked to an
activated negatively charged Biodyne C membrane. After
washing, the membrane was incubated for 60 min at 42uC with
peroxidase labelled streptavidin conjugate. For chemiluminescent
detection of hybridising DNA, the membrane was incubated in
ECL detection liquid (Amersham Biosciences, Uppsala, Sweden)
and exposed to LumiFilm (Roche, Indianapolis, IN, USA) for
5 min.
Detected HPV types were classified into low-risk (LR) (HPV 6,
11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89), high-risk (HR) (HPV
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,) and probably
high-risk (pHR) (HPV 26, 53, 66, 73, 82) types of the genus Alpha
that contains the mucosal types of HPV [27–29]. In our analyses,
we defined HPV 31 and 45 as closely related to and HPV 33, 52
and 58 as a distantly related to HPV 16 and/or 18.
To confirm the presence and integrity of the human DNA, beta-
globin PCR analysis by PC03/04 primer set [30] was performed
for all RLB assay negative specimens. Beta-globin negative
specimens were excluded from our study.
The laboratory is accredited according to C ˇSN EN ISO 15 189
and participates regularly in external control of quality programs
organized by INSTAND (Germany) and Mendel Center for
Biomedical Sciences (Cyprus). Furthermore, the laboratory
participated twice in WHO HPV LabNet Proficiency Study of
HPV DNA Typing organized by the WHO HPV Global
Reference Laboratory [31].
HPV sequencing
To determine the type of HPV in the specimens positive by
RLB only on the agarose gel but not by RLB hybridization, the
remaining aliquots of PCR amplicons were used for nucleotide
sequencing. The 150 bp products were cut out of the 2% NuSieve
GTG agarose gel (BMA, Rockland, ME), purified using the
MinElute
TMGel Extraction Kit (Qiagen, Hilden, Germany) and
directly sequenced using the BigDyeH Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Warrington, UK). The
sequence analysis was performed on the ABI PRISM 310 genetic
analyzer (Applied Biosystems) and the sequences were analyzed by
Chromas software and evaluated by BLAST software (http://
www.ncbi.nlm.nih.gov/BLAST/).
Statistical analyses
Multiply infected samples were those in which two or more
HPV types had been detected. Such samples were counted as
positive for one type of HPV and also included among positives for
the others. Type-specific HPV prevalence rates are expressed as
percentages of all cases tested for HPV, and thus represent the
HPV prevalence in either single or multiple infections. The
differences in the mean age were assessed by a one-way analysis of
variance (ANOVA) test. For contingency tables, the standard chi-
square test and the Fisher exact test were used. The prevalence
ratios in SCC in comparison to CIN2, 3 and CIN1 with 95%
confidence intervals (CI) were determined using GraphPad InStat
(version 3.00) (GraphPad Software, San Diego, CA). All tests were
two sided and the significance level was p=0.05. For assessing the
possible impact of HPV vaccines on the prevention of HPV-
associated cancer, we estimated the number of cervical cancer
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Republic. We used the numbers of incident cases of cervical,
vulvar and anal cancers in the Czech Republic published in 2010
[15] and type-specific HPV distribution derived from this study. A
woman with multiple infections was assigned in proportional
fractions to each genotype but counted only once [32].
Results
HPV genotyping of carcinomas
Altogether, 157 carcinomasampleswere availablefor HPVDNA
testing. Patients with SCC were significantly younger (P,0.001)
than those with other types of carcinomas (see materials and
methods). One hundred and eighteen (75%) carcinomas samples
wereHPVDNApositive.ThepresenceofHRHPVwasdetected in
95%(82/86) ofSCCsamples,35%(17/49) ofVCsamples and82%
(18/22) of AC samples. One vulvar carcinoma sample was only
infected with a LR HPV genotype only (HPV 42). No LR types as a
single infection were found in carcinoma samples from other
anatomical locations (Table 1). Multiple infection (coinfection with
two or more HPV types) was only found in 20% of SCC (17/86).
Coinfection with HPV 16 and 18 was the most commmon of
multiple infections (5/17). HPV 16 coinfection with HR HPV types
other than HPV18 was also often observed (11/17).
Overall, we detected 9 HR (HPV 16, 18, 31, 33, 39, 45, 52, 56,
58) 2 pHR (HPV 53, 73) and 1 LR (HPV 42) HPV types in
different types of carcinomas, of which 11 different HPV
genotypes were found in SCC samples while the spectrum of
HR HPV types in other types of carcinomas was much narrower.
Only HR HPV types 16, 33 and 45 were found as a single
infection. HPV 16 was the most prevalent type in cervical 73%
(63/86), vulvar 25% (12/49) and anal 82% (18/22) carcinomas,
followed by HPV 33, 45, 18, and 31 in descending order.
HPV vaccinal types (HPV 16 and/or 18) were detected as a
single infection in 50% (79/157) of tumors and as a coinfection
with other HR HPV types in additional 10% (16/157) of samples.
Altogether, 61% (95/157) of analyzed malignant tumors contained
one or both vaccinal types. The presence HPV types either closely
or distantly related to the vaccinal ones, i.e. HPV 31 and 45 and
HPV 33, 52, and 58, respectively, was detected in additional 5%
(8/157) and 11% (11/157) of carcinoma specimens, respectively.
Sixty-five (76%) of 86 cervical cancer samples contained HPV 16
and/or 18 as a single or multiple infection. The presence of HPV
types either closely or distantly related to the vaccinal ones, i.e.
HPV 31 and 45 and HPV 33, 52, and 58, was detected in
additional 8% (7/86) and 8% (7/86) of SCC samples, respectively.
HPV genotyping of precancerous lesions
A total of 695 precancerous lesion samples were available for
our analyses: 338 from CIN1 cases, 111 from CIN2 and 200 from
CIN3 cases and 46 from VIN cases. Median age of women with
cervical lesions was substantially and statistically significantly lower
(P,0.0001) compared to that of patients with VIN (see study
design). Overall, the prevalence of HPV DNA was 76% (528/695).
HPV infection was detected in 62% (209/338) of CIN1 samples,
77% (85/111) of CIN2 and 94% (188/200) of CIN3 samples and
100% (46/46) of VIN samples (Table 2). Among the HPV-positive
samples, 4% (19/528) were infected with LR HPV types only.
In comparison to carcinomas, precancerous lesions contained a
larger variety of HPV types. As shown in Table 2, altogether 28
different HPV genotypes were detected: 13 were HR (HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), 4 pHR (HPV 26, 53, 66,
82) and 9 LR (HPV 6, 11, 40, 42, 43, 54, 70, , 81, 89) and 2
undetermined (HPV 55, 71). Most of these types were present in
cervical lesions. The VIN samples were infected with 6 different
HR (HPV 16, 18, 33, 45, 56, 59) and 3 LR (HPV 6, 11, 43) HPV
types. Similar to carcinomas, HPV 16 was the most prevalent type
in all types of precancerous lesions followed by HPV 33, 31, 18,
and 45. HPV 16 was observed in 28% (96/338) of CIN1 samples,
41% (46/111) of CIN2 and 68% (135/200) of CIN3 samples and
72% (33/46) of VIN samples.
More than a half of samples contained a single HPV type (56%).
Multiple infection was found most commonly in cervical
precancerous lesion samples: in 20% (66/338) of CIN1, 21%
(23/111) of CIN2 and 22% (44/200) of CIN3 samples. Most
multiple infections were coinfections with two or three HPV types.
Coinfection with four HPV genotypes was only found in six
cervical lesion samples.
The vaccinal types HPV 16 and/or 18 were present in 34%
(239/695) of precancerous lesion samples as a single infection, in
1% (8/695) as a multiple infection (combined HPV16/18
infection), and in 13% (87/695) in combination with other HPV
types. The presence of the types either closely or distantly related
types to the vaccinal ones: HPV 31 and 45 and HPV 33, 52, and
58, respectively, was detected in 9% (59/695) and 11% (79/695) of
samples, respectively.
Table 1. HPV prevalence in carcinomas of different
anatomical locations.
Diagnosis
SCC VC AC Total
Sample N 86 49 22 157
Prevalence [%]
HPV + 95.3 36.7 81.8 75.2
Single HPV 75.6 36.7 81.8 89.2
Multiple HPV 19.8 0.0 0.0 10.8
Any HR type 95.3 34.7 81.8 74.5
16 73.3 24.5 81.8 59.2
18 8.1 0.0 0.0 4.5
31 7.0 0.0 0.0 3.8
33 10.5 8.2 0.0 8.3
39 1.2 0.0 0.0 0.6
45 9.3 2.0 0.0 5.7
52 1.2 0.0 0.0 0.6
53 1.2 0.0 0.0 0.6
56 2.3 0.0 0.0 1.3
58 3.5 0.0 0.0 1.9
73 1.2 0.0 0.0 0.6
16/18
# 75.6 24.5 81.8 60.5
31/45* 8.1 2.0 0.0 5.1
33/52/58** 8.1 8.2 0.0 7.0
Any LR type 0.0 2.0 0.0 0.6
42 0.0 2.0 0.0 0.6
6/11*** 0.0 0.0 0.0 0.0
SCC=squamous cell cervical carcinoma, VC=vulvar carcinoma, AC=squamous
cell anal carcinoma.
#samples HPV 16 and/or 18 positive.
*samples which do not contain HPV 16 and/or 18.
**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.
***samples which do not contain HPV 16 and/or 18.
doi:10.1371/journal.pone.0021913.t001
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of CIN1, CIN2 and CIN3 samples, respectively, were positive for
HPV 16 and/or 18. Closely related types HPV 31 and 45 were
present in 9% (31/338),11% (12/111) and 7% (14/200) of
samples, respectively, and distantly related types HPV 33, 52, and
58 in 9% (30/338), 14% (16/) and 13% (25/100) of samples,
respectively. LR HPV types were detected in 9% of precancerous
lesion samples. HPV 6 and/or 11 were present as either a single or
multiple infection in 3% of all precancerous lesion samples, more
precisely in 5% (18/338) of CIN1 samples, 1% (1/111) of CIN2
and 1% (1/200) of CIN 3 samples and 9% (4/46) of VIN samples.
HPV genotyping of condylomata acuminata
HR HPV types as a single infection were only detected in 4%
(2/54) of VCA samples and as a multiple infection together with
LR types in additional 15% (8/54) of VCA samples, while ACA
samples did not contain any HR HPV type, with a single sample
being positive for two LR types. In VCA samples, 11 different
HPV types were detected: 4 were HR (HPV 16, 33, 45, 51), 2
pHR (HPV 26, 73) and 5 LR (HPV 6, 11, 42, 84, 81) HPV types
(Table 3).
Altogether, vaccinal HPV types 6 and/or 11 were present in
84% (54/64) of condyloma acuminatum samples from different
anatomical locations, in 87% (47/54) of VCA samples, and 70%
(7/10) of ACA samples.
Table 2. HPV prevalence in precancerous lesions of different
anatomical locations.
Diagnosis
CIN1
(%)
CIN2
(%)
CIN3
(%)
VIN
(%)
Total
(%)
Sample N 338 111 200 46 695
HPV + 61.8 76.6 94.0 100.0 76.0
Single HPV 42.0 55.9 72.0 87.0 56.0
Multiple HPV 19.8 20.7 52.0 13.0 28.8
Any HR type 57.4 73.9 93.5 93.5 72.5
16 28.4 41.4 67.5 71.7 44.6
18 5.3 4.5 5.5 4.3 5.2
26 0.3 0.9 0 0 0.3
31 8.6 8.1 14.5 0 9.4
33 6.8 11.7 14.0 17.4 10.4
35 3.0 2.7 1.0 0 2.2
39 0.3 1.8 0 0 0.4
45 4.7 6.3 3.0 4.3 4.5
51 3.8 3.6 1.5 0 2.9
52 2.1 5.4 2.0 0 2.4
53 0 0.9 0 0 0.1
56 3.6 3.6 3.0 2.2 3.3
58 4.4 2.7 5.5 0 4.2
59 0.9 0 0 2.2 0.6
66 1.8 1.8 1.5 0 1.6
68 0 . 6 000 0 . 3
82 0 0 2.0 0 0.6
Undetermined 0.3 0.9 0 0 0.3
55 0 0.9 0 0 0.1
71 0 . 3 000 0 . 1
16/18
# 32.5 43.2 70.5 71.7 43.0
31/45* 9.2 10.8 7.0 4.3 8.3
33/52/58** 8.9 14.4 12.5 17.4 11.4
Any LR type 12.4 4.5 4.0 10.9 8.6
6 4.1 1.8 0.5 6.5 2.9
11 2.4 0 0.5 2.2 1.4
40 0 . 3 000 0 . 1
42 2.1 0 1.5 0 1.4
43 0.6 0.9 0 2.2 0.6
54 0.9 0.9 0.5 0 0.7
70 1.5 0.9 0.5 0 1.0
81 1.2 0.9 0.5 0 0.9
89 0 . 9 000 0 . 4
6/11*** 5.3 0.9 0.5 8.7 2.9
CIN1=cervical intraepithelial neoplasia grade 1, CIN2/3= cervical intraepithelial
neoplasia grade 2 and 3, VIN=vulvar intraepithelial neoplasia.
#samples HPV 16 and/or 18 positive.
*samples which do not contain HPV 16 and/or 18.
**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.
***samples which do not contain HPV 16 and/or 18.
doi:10.1371/journal.pone.0021913.t002
Table 3. HPV prevalence in condyloma acuminata of different
anatomical locations.
Diagnosis
VCA ACA Total
Sample N 54 10 64
Prevalence [%]
HPV + 94.4 70.7 90.6
Single HPV 75.9 60.0 73.4
Multiple HPV 18.5 10.0 17.2
Any HR type 18.5 0 15.6
16 1.9 0 1.6
26 3.7 0 3.1
33 3.7 0 3.1
45 1.9 0 1.6
51 1.9 0 1.6
73 5.6 0 4.7
16/18
# 1.9 0 1.6
31/45* 1.9 0 1.6
33/52/58** 3.7 0 3.1
Any LR type 90.7 100.0 89.1
6 75.9 50.0 71.9
11 18.5 30.0 20.3
42 3.7 0 3.1
84 1.9 0 1.6
81 1.9 0 1.6
6/11*** 87.0 70.0 84.4
VCA = vulvar condyloma acuminatum, ACA = anal condyloma acuminatum.
#samples HPV 16 and/or 18 positive.
*samples which do not contain HPV 16 and/or 18.
**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.
***samples which do not contain HPV 16 and/or 18.
doi:10.1371/journal.pone.0021913.t003
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and CIN3 cases
The overall prevalence of HPV was higher in SCC (95%) in
comparison to CIN1 (62%) (SCC:CIN1 ratio 1.5, 95% CI 1.4–
1.7), CIN2 (77%) (SCC:CIN2 ratio 1.2, 95% CI 1.1–1.4) but not
in CIN3 (94%) (SCC:CIN3 ratio 1.0, 95% CI 1.0–1.1) cases.
Similar results were obtained for any HR HPV type detected and
for seven HR HPV types most prevalent in SCC samples (Table 4).
For each of the seven HPV types, the SCC:CIN1, SCC:CIN2 and
SCC:CIN3 ratios were also calculated. The respective ratios were
2.6, 1.8 and 1.1 for HPV 16, 1.5, 1.8 and 1.5 for HPV 18 and 2.0,
1.5 and 3.1 for HPV 45. For HPV types closely related (HPV 31,
33, 56), or distantly related (HPV 58) the SCC:CIN3 ratios were
0.5 to 0.8, respectively (Table 4).
Cervical, vulvar and anal cancers associated with specific
HPV types
In the Czech Republic 1300 cervical, vulvar and anal incident
cancer cases occur, more precisely 990 cervical cancer cases, 189
vulvar cancer cases, and 121 anal cancer cases [15]. We estimated
the number of cases that can be attributed to the 8 most prevalent
HPV types from this study (HPV 16, 18, 31, 33, 45, 52, 58, and
73). The proportion of cancer cases attributed to the 8 most
prevalent HPV types was 74.5% which corresponds to 961 cancer
cases. The particular rates were 94.2% for SCC, 34.7% for VC
and 81.8% for AC. The eight most prevalent HPV types account
for 932 SCC, 66 VC, and 99 AC cases in the Czech republic
(Figure 1).
Discussion
In this study we provide the largest summary data on the type-
specific HPV type specific prevalence in the population of Czech
women and men with diseases of the anogenital tract associated
with HPV infection. Importantly, the prevalence rates of the
vaccinal HPV types as well as those of HPV types which have
shown a partial cross protection in clinical trials [33–36] are
reported. The results of this study allow estimating potential
benefit that can be achieved by the implementation of routine
vaccination in the Czech Republic. Furthermore, these results will
be used as inputs for models for estimating the impact of different
strategies for the prevention of HPV-associated diseases.
In this study we analyzed 157 squamous cell carcinoma samples,
695 precancerous lesion samples and 64 condylomata acuminata
samples from different anatomical locations. A very sensitive
method was used, which is based on the amplification of a short
DNA fragment of HPV L1 ORF and allows detection of multiple
HPV infections [26]. This method is also recommended for HPV
detection in primary screening by the European Guidelines for
Quality Assurance in Cervical Cancer Screening [37]. Further-
more, the classification of all samples analyzed in this study, except
for 14% of CIN1 samples, was confirmed by histology.
The data on HPV prevalence in precancerous cervical lesions
and invasive cervical cancer cases in the Czech Republic were
evaluated previously on another set of specimens [21]. The HPV
prevalence was much lower in the previous study compared to the
present one (53% vs. 62% in CIN1 samples, 58% vs. 88% in
CIN2/3 samples and 74% vs. 95% SCC samples) as were the
numbers of different HPV types (16 HR, 5 LR und 1
undetermined HPV types vs. 17 HR, 9 LR HPV types and 2
undetermined). Even though yielding very important results, our
previous study had some limitations. Relatively small numbers of
precancerous cervical lesion samples and cervical carcinoma
samples were analyzed (87 CIN1, 88 CIN2+, and 49 SCC
samples). The PCR method then used for HPV detection, in wide
use at that time, has shown limited sensitivity in comparison to
other newly introduced ones [38]. Finally, the severity of
precancerous lesions was not confirmed for all cases by histology
in our previous study. Therefore, the discrepancy in results
between our two studies can be most likely attributed to the above-
mentioned factors.
The published data on the type-specific HPV prevalence in
patients with HPV-associated diseases in the Central and East
European countries are scarce and most studies have analyzed
only very small numbers of specimens. While more studies from
Central and East Europe on HPV prevalence in CC were
published and included in the meta-analyses [9], the HPV
Table 4. Comparison of overall and type-specific HPV prevalence between CIN1 and SCC, CIN2 and SCC, and CIN3 and SCC cases.
CIN1:SCC CIN2:SCC CIN3:SCC
HPV type PREVALENCE RATIO PREVALENCE RATIO PREVALENCE RATIO
RR 95%CI P RR 95%CI P RR 95%CI P
All** 1.5 1.40–1.70 ,0.0001 1.2 1.11–1.39 0.0002 1.0 0.96–1.08 0.784
Any HR*** 1.7 1.50–1.84 ,0.0001 1.3 1.13–1.43 ,0.0001 1.0 0.96–1.08 0.786
7 HR**** 1.8 1.61–2.05 ,0.0001 1.7 1.44–2.06 ,0.0001 1.0 0.95–1.09 0.814
16 2.6 2.09–3.19 ,0.0001 1.8 1.37–2.28 ,0.0001 1.1 0.92–1.27 0.402
18 1.5 0.66–3.54 0.312 1.8 0.59–5.50 0.372 1.5 0.59–3.69 0.430
31 0.8 0.35–1.90 0.826 0.9 0.32–2.33 1.000 0.5 0.22–1.21 0.157
33 1.5 0.74–3.20 0.256 0.9 0.40–1.99 0.824 0.8 0.37–1.52 0.450
45 2.0 0.87–4.44 0.117 1.5 0.56–3.91 0.589 3.1 1.11–8.67 0.034
56 0.7 0.15–2.87 0.745 0.7 0.12–3.44 0.698 0.8 0.16–3.77 1.000
58 0.8 0.23–2.66 1.000 1.3 0.27–6.24 1.000 0.6 0.18–2.22 0.564
95%CI=95% confidence interval, RR= relative risk, P= probability.
**all HPV types detected (LR and HR).
***all HR HPV types detected.
****HR HPV types 16, 18, 31, 33, 45, 56, and 58.
doi:10.1371/journal.pone.0021913.t004
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republic [7] and that in CIN2+ samples for the Czech Republic
and Hungary [9,13]. Recently few additional studies from the
Central and East European region have been published
[17,39,40], but only that of Bardin et al. [17] reported on a
larger number of SCC patients. Two meta-analyses [9,13] have
concordantly shown an overall rate of 85% of HPV positivity of
SCC samples in Europe. The prevalence rates ranged from 53 to
100% and that for the Czech Republic is 95%, as determined in
this study. The most prevalent HPV types in SCC in Europe are,
in descending order, HPV 16, HPV 18, and HPV 45. In our
study, the second most common type was HPV 33, followed by
HPV 45 and HPV 18. Since only squamous cell carcinoma
samples were included in our study, the reported HPV type
prevalence data is in agreement with the results of the meta-
analysis of Smith et al. who has shown variation in type-specific
HPV prevalence between squamose cell carcinomas and adeno-
carcinomas [9]. In accordance with Smiths data for the Europe
region, HPV 56 is more common in the Czech Republic than
HPV 52 which is more prevalent in SCC in other regions of the
world [41]. Despite the fact that HPV 35 was the sixth most
prevalent type in SCC in the recently published study by de
Sanjose et al. [41], we didnt detect this HPV type in our cohort of
SCC patients. In the previous meta-analyses the majority of
studies from Europe didnt find HPV 35 in SCC as well, regardless
of method used for HPV detection [9,13]. Since in the WHO
proficiency study [31] both methods; SPF-10 PCR used in the
recent study and GP5+/6+ RLB used in our study, proofed to be
very sensitive for the detection of HPV 35, we conclude that
discrepant findings can be explained only by the differences in the
number of cases studied (86 SCC specimens vs. 2093 SCC
specimens from Europe) [41].
The type-specific HPV prevalence in CIN2+ samples found in
our study, is the same as the data reported for Europe (88%), with
the exception of HPV 16 and/or 18 (61 vs. 52%) [9]. The
prevalence rates of other HPV types detected were similar to
those observed in Europe, apart from HPV 73 that was not
recovered from CIN2+ cases in the Czech Republic, most likely
as a result of the use of a less sensitive assay for the detection of
HPV 73 [42].
In comparison to the summary data for Europe as published by
Clifford et al. [7], the type-specific HPV prevalence in CIN1 cases
in our study was quite different. We detected about a one third
higher prevalence of HPV 16 (28 vs. 19%), but much lower
prevalence rates of HPV 59 (1% vs. 3%), HPV 39 (0.3% vs. 3%),
HPV 66 (2% vs. 6%), HPV 52 (2% vs. 5.4%), and HPV 53 (0% vs.
3.7%). The spectrum of HPV types present in CIN1 cases is much
wider in comparison to CIN2+ and SCC, with the low prevalent
types being more common. Our group has previously reported
that the detection of low prevalent types can vary greatly between
different assays and that RLB with GP5+/6+ primers has lower
sensitivity for HPV 52, 53, and 59 [42]. This could explain some of
the discrepant findings.
The present study has shown a significantly higher prevalence of
any HPV type, as well as of HR HPV type among SCC cases in
comparison to CIN1 (p,0.0001 for both)and CIN2 cases
(p=0.0002 and p,0.0001, respectively) (Table 4). The prevalence
was also higher for the seven HPV types most prevalent in SCC.
HPV 16 was significantly more prevalent in SCC cases in
comparison both to CIN1 (p,0.0001) and CIN2 (p,0.0001) cases
but not to CIN3 cases (p=0.402). Prevalence ratios above one
were recorded for HPV 18, 45 and 58, while for other HPV types,
the ratios ranged between 0.5 and 0.9, but except for HPV 45
(p=0.034) in CIN3 in comparison to SCC, the differences were
not statistically significant. Since our data are comparable to the
ratios reported by Clifford et al. [6] for a large number of cases, we
conclude that the lack of statistical significance for HPV types
other than HPV 16 is due to the small numbers of subjects positive
for HPV types other than HPV 16.
A meta-analysis of HPV prevalence studies in precancerous
lesions and vulvar and anal carcinomas [11,12] included our
previously published data from the Central and Eastern European
region and those from Poland and Austria. Recently studies of
Kowalewska et al. [43] and Garland et al. [44] have reported on
HPV prevalence in vulvar cancer in Poland and Austria. In our
study, the HPV prevalence in VIN cases was 100%. Most other
studies which have reported comparably high prevalence rates
only included patients with VIN 3. We have detected HPV in all
VIN samples, including VIN 1 and 2. The most prevalent type was
HPV 16, followed by HPV 33, 18, and 45. This finding is in
agreement with the summary data reported by de Vuyst et al. [12],
except the prevalence rates of HPV 33 and 45 were higher in this
study. The lower average rates in the meta-analysis are due much
Figure 1. Cumulative percentages of cancer cases of women
and men in the Czech Republic. Cumulative percentages of cervical
(A), vulvar (B) and anal (C) cancer cases in women and men occurring
every year in the Czech Republic that are attributed to eight most
prevalent HPV types (990, 189 and 121 incident cancer cases,
respectively). (Sdapted from Munoz, 2004)[46].
doi:10.1371/journal.pone.0021913.g001
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detection of HPV 45 in VIN.
The overall prevalence of HPV as well as HPV type distribution
in VC is in our study comparable to other studies. Nowadays it is
widely accepted that about 40% of VC cases can be etiologically
linked to HPV.
Importantly, focused on the prevalence of both vaccinal and
cross-reactive HPV types, this study revealed that altogether 43%
of precancerous lesions of the cervix and vulva (33% of CIN1,
43% of CIN2, 71% of CIN3 and 72% of VIN) are caused by HPV
16 and/or 18 and additional 20% by HPV types related to the
vaccinal ones (HPV 31, 45, 33, 52, 58). Therefore, a substantial
number of precancerous lesions can be considered preventable by
prophylactic vaccination in the Czech Republic. The vaccinal LR
HPV types HPV 6 and/or 11 were detected in 5% of CIN1, as few
as 1% of CIN2 and 0.5% CIN3 and 9% of VIN cases.
The overall prevalence of HPV 16 and/or 18 among the
analyzed cancer cases was 61% and that of the closely or distantly
related types was 12%. The lowest prevalence of HPV 16/18 was
observed in VC cases. Based on our data, the development of
vulvar cancer can be prevented in about half of cases, thus
reducing the need for mutilating surgery that dramatically reduces
quality of life for patients.
The rate of SCC cases attributable to HPV 16/18 infection in
the Czech population is 76%. Even higher is the involvement of
HPV 16/18 in AC cases (82%). In view of cross-protective effect of
the available vaccines, we can expect the potential benefit from
vaccination against HPV in preventing SCC to be as high as 92%
for the Czech population.
Finally, specimens with the histologically confirmed presence of
condylomata acuminata were analyzed. Even though only a
limited number of samples were available, the information is very
important for the planning of the preventive strategies. We have
shown that 89% of these lesions are infected by LR HPV types,
with vaccinal types HPV 6/11 being present in 84% of them.
These data should be taken into account when considering
population-based prophylactic vaccination against HPV.
In conclusion, our study reports on the type-specific prevalence
of HPV in benign, premalignant and malignant lesions of the
anogenital tract in women and man. The prevalence and spectrum
of HPV types detected in the Czech Republic are comparable to
the data reported for European countries. The observed
differences can be mostly attributed to the variation in the
methods used for HPV detection. The proportion of patients
infected with vaccinal and closely or distantly related HPV types is
much higher than originally proposed. Approximately 952 of 1300
incident cancer cases (CC, VC and AC) and 921 of 990 CC cases
can be attributed to these HPV types in the Czech Republic.
Furthermore, it has been shown that the implementation of
routine vaccination not only resulted in decrease in incidence of
atypical cervical cytology and precancerous cervical lesions but
also in the reduced need for colposcopy and invasive treatment
procedures [45]. Therefore, we strongly advocate a rapid
implementation of routine HPV vaccination in the Czech
Republic which can significantly reduce the burden of HPV-
associated diseases as well as the national healthcare expenditures.
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